Catherine Salussolia, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, AMPA | 4 | 2017 | 331 | 0.980 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2017 | 895 | 0.450 |
Why?
|
| Protein Subunits | 3 | 2013 | 960 | 0.420 |
Why?
|
| Eukaryotic Cells | 1 | 2013 | 198 | 0.410 |
Why?
|
| Tuberous Sclerosis | 2 | 2021 | 1029 | 0.410 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2011 | 70 | 0.410 |
Why?
|
| Protein Multimerization | 3 | 2017 | 971 | 0.360 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2108 | 0.350 |
Why?
|
| Cimetidine | 1 | 2007 | 78 | 0.300 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2007 | 143 | 0.270 |
Why?
|
| Body Temperature | 1 | 2007 | 777 | 0.230 |
Why?
|
| Pain Threshold | 1 | 2007 | 585 | 0.220 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2021 | 117 | 0.190 |
Why?
|
| Adaptor Protein Complex 4 | 1 | 2020 | 38 | 0.180 |
Why?
|
| Analgesics | 1 | 2007 | 1040 | 0.180 |
Why?
|
| Purkinje Cells | 1 | 2021 | 223 | 0.180 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2019 | 22 | 0.180 |
Why?
|
| Mental Disorders | 1 | 2019 | 6601 | 0.170 |
Why?
|
| Protein Structure, Secondary | 2 | 2013 | 1246 | 0.170 |
Why?
|
| Vigabatrin | 1 | 2019 | 92 | 0.160 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 12075 | 0.160 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2020 | 157 | 0.160 |
Why?
|
| Mutagenesis | 2 | 2011 | 1267 | 0.150 |
Why?
|
| HEK293 Cells | 4 | 2017 | 4201 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 3846 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2020 | 737 | 0.130 |
Why?
|
| Ion Channel Gating | 2 | 2017 | 437 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2014 | 5458 | 0.120 |
Why?
|
| Neurogenesis | 1 | 2019 | 838 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 941 | 0.110 |
Why?
|
| Copper Sulfate | 1 | 2011 | 14 | 0.100 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 23 | 0.100 |
Why?
|
| Kynurenic Acid | 1 | 2011 | 45 | 0.100 |
Why?
|
| 4-Aminopyridine | 1 | 2011 | 81 | 0.100 |
Why?
|
| Microinjections | 1 | 2011 | 327 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 898 | 0.090 |
Why?
|
| Xenopus | 1 | 2011 | 712 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2011 | 449 | 0.080 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 936 | 0.080 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 964 | 0.080 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 1939 | 0.080 |
Why?
|
| Rats | 4 | 2017 | 24273 | 0.080 |
Why?
|
| Glycine | 1 | 2011 | 671 | 0.080 |
Why?
|
| Membrane Potentials | 1 | 2011 | 1137 | 0.080 |
Why?
|
| Xenopus laevis | 1 | 2011 | 957 | 0.080 |
Why?
|
| Stroke | 2 | 2019 | 9981 | 0.070 |
Why?
|
| Cysteine | 1 | 2011 | 874 | 0.070 |
Why?
|
| Oocytes | 1 | 2011 | 1187 | 0.070 |
Why?
|
| Sulfides | 1 | 2007 | 166 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2019 | 2790 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2011 | 1770 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2011 | 1169 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2886 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3265 | 0.060 |
Why?
|
| Genotype | 1 | 2019 | 12956 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2013 | 3748 | 0.060 |
Why?
|
| Transfection | 1 | 2011 | 5892 | 0.060 |
Why?
|
| Animals | 7 | 2021 | 168788 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6367 | 0.050 |
Why?
|
| Phenotype | 1 | 2019 | 16365 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15538 | 0.050 |
Why?
|
| Mutation | 2 | 2019 | 29784 | 0.050 |
Why?
|
| Imidazoles | 1 | 2007 | 1206 | 0.050 |
Why?
|
| Neurons | 1 | 2019 | 9335 | 0.040 |
Why?
|
| Piperidines | 1 | 2007 | 1605 | 0.040 |
Why?
|
| Ribosomes | 1 | 2021 | 500 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 506 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2007 | 1973 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2011 | 13036 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 23404 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 8302 | 0.030 |
Why?
|
| Humans | 10 | 2020 | 744220 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Infant | 3 | 2020 | 35129 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1462 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35423 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2020 | 40992 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 4465 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7799 | 0.020 |
Why?
|
| Child | 3 | 2020 | 77679 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 85759 | 0.020 |
Why?
|
| Registries | 1 | 2020 | 8090 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 6116 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 56436 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 4586 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18027 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7281 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2019 | 77426 | 0.010 |
Why?
|
| Male | 3 | 2020 | 350027 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7659 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2019 | 25618 | 0.010 |
Why?
|
| Algorithms | 1 | 2019 | 13885 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40559 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 81178 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 63119 | 0.010 |
Why?
|
| Female | 2 | 2020 | 380197 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 213367 | 0.000 |
Why?
|
| Adult | 1 | 2020 | 214035 | 0.000 |
Why?
|